Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study
Launched by ZHONG WANG · Aug 19, 2018
Trial Information
Current as of July 24, 2025
Unknown status
Keywords
ClinConnect Summary
Xueshuantong-Injection is a kind of natural compound injection with Panax notoginseng saponins(PNS). It's a popular drug for improving blood circulation that focusing on central retinal vein occlusion, stroke sequela, internal ophthalmopathy, hyphema and so on. However, more and more case reports about the adverse drug events of Panax notoginseng saponins have been reported in recent years. Therefore, this registry of Xueshuantong-Injection aims to monitor the safety and find the incidence of adverse drug reactions to Xueshuantong-Injection. Moreover, this registry is highly concerned on id...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who use Xueshuantong-Injection in the monitoring departments of certain hospitals
- Exclusion Criteria:
- • None
About Zhong Wang
Zhong Wang is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing cutting-edge therapies, Zhong Wang collaborates with leading research institutions and healthcare professionals to conduct rigorous clinical trials that prioritize patient safety and efficacy. The organization is driven by a mission to improve health outcomes through the timely delivery of novel treatments, leveraging a robust infrastructure and expertise in regulatory compliance. Zhong Wang's commitment to transparency and ethical standards ensures that all trials are conducted with the highest level of integrity, contributing to the advancement of medical science and the betterment of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hengshui, Hebei, China
Nanyang, Henan, China
Sanmenxia, Henan, China
Zhoukou, Henan, China
Wuhan, Hubei, China
Lianyungang, Jiangsu, China
Yichun, Jiangxi, China
Dalian, Liaoning, China
Lingyuan, Liaoning, China
Binzhou, Shandong, China
Weihai, Shandong, China
Jincheng, Shanxi, China
Jinzhong, Shanxi, China
Yuanping, Shanxi, China
Patients applied
Trial Officials
Zhong Wang, M.D.
Study Director
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Jinmin Liu, M.D.
Principal Investigator
Dongfang Hospital Affiliated to Beijing University of traditional Chinese medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials